Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era

• Published in: Cancer medicine (Malden, MA) Vol. 11; no. 4; pp. 1109 - 1118
• Main Authors: Yang, Shan‐Shan, Pang, Ya‐Jun, Wang, Zhi‐Qiang, Zhang, Bao‐Yu, Liu, Zhi‐Qiao, Chen, En‐Ni, OuYang, Pu‐Yun, Xie, Fang‐Yun
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2022; John Wiley and Sons Inc; Wiley
• Subjects: Cancer therapies; Chemoradiotherapy; Chemoradiotherapy - adverse effects; Chemoradiotherapy - methods; Chemotherapy; Clinical Cancer Research; concurrent chemoradiotherapy; Dehydrogenases; DNA viruses; Epstein-Barr virus; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; intensity‐modulated radiotherapy; L-Lactate dehydrogenase; Lactic acid; Lymphatic system; Magnetic resonance imaging; Medical prognosis; Multivariate analysis; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - pathology; Nasopharyngeal Neoplasms - pathology; Patients; Plasma; Radiation therapy; Radiotherapy, Intensity-Modulated - adverse effects; Radiotherapy, Intensity-Modulated - methods; Retrospective Studies; Risk Factors; Risk groups; Software; Statistical analysis; Survival; Throat cancer; Tomography; tumor burden; Tumors; intensity-modulated radiotherapy; nasopharyngeal carcinoma; tumor burden; concurrent chemoradiotherapy

Purpose We aimed to develop and prospectively validate a risk score model to guide individualized concurrent chemoradiotherapy (CCRT) for patients with stage II nasopharyngeal carcinoma (NPC) in intensity‐modulated radiotherapy (IMRT) era. Materials and Methods In total, 1220 patients who received C...